RT Journal Article
SR Electronic
T1 Effect of Ibandronate on Disseminated Tumor Cells in the Bone Marrow of Patients with Primary Breast Cancer: A Pilot Study
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 3623
OP 3628
VO 31
IS 10
A1 HOFFMANN, OLIVER
A1 AKTAS, BAHRIYE
A1 GOLDNAU, CORNELIA
A1 HEUBNER, MARTIN
A1 OBERHOFF, CARSTEN
A1 KIMMIG, RAINER
A1 KASIMIR-BAUER, SABINE
YR 2011
UL http://ar.iiarjournals.org/content/31/10/3623.abstract
AB Background: Breast cancer patients may experience disease relapse even 10-20 years after primary diagnosis. Recurrence is caused by dormant disseminated tumor cells (DTCs) in the bone marrow (BM). Whereas chemotherapy is unable to eradicate these non-proliferating cells, bisphosponates are currently being discussed as eliminating DTCs. The purpose of our study was to: i) analyze the presence of DTCs in the BM of breast cancer patients 2-10 years after first diagnosis of cancer, and ii) to study the effect of ibandronate on DTCs in those patients with DTC persistence. Patients and Methods: Bilateral BM aspirates of 54 individuals diagnosed 2-10 years ago with breast cancer, but currently disease free, were analyzed for DTCs by immunocytochemistry using pan-cytokeratin antibody A45-B/B3. Patients with DTC persistence received oral ibandronate treatment (50 mg per day) for six months and bilateral BM aspirates were analyzed for DTCs again after therapy. Results: DTCs were found in 18/54 (33%) of the patients, with a median number of 3 disseminated tumor cells (range 1-6 cells). These 18 patients received ibandronate orally for 6 months and 17/18 patients were analyzed for DTCs again after therapy. Only 3/17 (18%) patients remained DTC-positive, with the detection of 1 (n=2 patients) and 3 DTCs, respectively. These three DTC-positive patients continued their ibandronate intake for a further six months and re-examination of the BM resulted in no detection of DTCs in any of the three patients. Conclusion: Our pilot study indicates the potential effect of ibandronate on DTCs and further studies are needed to demonstrate these findings in a larger patient cohort.